Biopharma industry questions potential AstraZeneca, Bristol Myers merger
The weekend report about a potential megamerger of AstraZeneca and Bristol Myers Squibb is raising a number of questions for both companies, according to biopharma analysts. Some of the motivation seems clear: ...
AstraZeneca and Bristol Myers Squibb are reportedly in talks about a potential merger. According to Handelsblatt, a person familiar with the matter said the combined company would have a market value of around $400 billion.
The talks may face significant hurdles, including antitrust concerns. Handelsblatt reports that there are concerns about how US competition authorities, under the Trump administration, would view the deal. A merger would see a British company take over a large US pharmaceutical company.
The two companies' portfolios have significant overlap, with both generating a substantial portion of their sales from cancer medications that compete with each other, according to Handelsblatt. AstraZeneca declined to comment, while Bristol Myers Squibb was not available for a statement.
Brief written by urgent.news from Endpoints News, Handelsblatt — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
